{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:01:07Z","timestamp":1771891267899,"version":"3.50.1"},"reference-count":41,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1055\/a-2752-2800","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T23:30:25Z","timestamp":1771889425000},"page":"229-236","source":"Crossref","is-referenced-by-count":0,"title":["Praxistipps Migr\u00e4neprophylaxe"],"prefix":"10.1055","volume":"151","author":[{"given":"Hans-Christoph","family":"Diener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagny","family":"Holle-Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251321500","article-title":"Evidence-based guidelines for the pharmacological treatment of migraine, summary version","volume":"45","author":"R Ornello","year":"2025","journal-title":"Cephalalgia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241305381","article-title":"Evidence-based guidelines for the pharmacological treatment of migraine","volume":"45","author":"R Ornello","year":"2025","journal-title":"Cephalalgia"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241269735","article-title":"International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine","volume":"44","author":"F Puledda","year":"2024","journal-title":"Cephalalgia"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrneurol.2016.93","article-title":"Chronic migraine: risk factors, mechanisms and treatment","volume":"12","author":"A May","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00415-023-12103-4","article-title":"Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study","volume":"271","author":"P Barbanti","year":"2024","journal-title":"J Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","article-title":"Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study","volume":"27","author":"HC Diener","year":"2007","journal-title":"Cephalalgia"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10194-017-0787-1","article-title":"Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design","volume":"18","author":"D Serrano","year":"2017","journal-title":"J Headache Pain"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s10194-022-01472-2","article-title":"Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis","volume":"23","author":"X Wang","year":"2022","journal-title":"J Headache Pain"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1111\/ene.15075","article-title":"Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study","volume":"28","author":"S Vries Lentsch","year":"2021","journal-title":"Eur J Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","article-title":"Systematic review of migraine prophylaxis adherence and persistence","volume":"20","author":"Z Hepp","year":"2014","journal-title":"J Manag Care Pharm"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/0333102414547138","article-title":"Adherence to oral migraine-preventive medications among patients with chronic migraine","volume":"35","author":"Z Hepp","year":"2015","journal-title":"Cephalalgia"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1212\/WNL.0b013e31824d5846","article-title":"Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine","volume":"78","author":"SD Silberstein","year":"2012","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1590\/s0004-282x2009000600002","article-title":"A double-blind randomized controlled trial of low doses of propranolol, nortriptyline, and the combination of propranolol and nortriptyline for the preventive treatment of migraine","volume":"67","author":"RB Domingues","year":"2009","journal-title":"Arq Neuropsiquiatr"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e2121","DOI":"10.1212\/WNL.0000000000008944","article-title":"Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy","volume":"94","author":"K Mullin","year":"2020","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40120-024-00586-w","article-title":"Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study","volume":"13","author":"T Alsaadi","year":"2024","journal-title":"Neurol Ther"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S1474-4422(07)70272-7","article-title":"Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebocontrolled trial","volume":"6","author":"HC Diener","year":"2007","journal-title":"Lancet Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s10194-021-01366-9","article-title":"In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study","volume":"22","author":"A Alpuente","year":"2021","journal-title":"J Headache Pain"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","article-title":"The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice","volume":"59","author":"American Headache Society","year":"2019","journal-title":"Headache"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1046\/j.1468-2982.1991.1106251.x","article-title":"Long-Term Results of Migraine Prophylaxis With Flunarizine and Beta-Blockers","volume":"11","author":"C Wober","year":"1991","journal-title":"Cephalalgia"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16203","article-title":"RE-START: Exploring the effectiveness of anti-calcitonin gene-related peptide resumption after discontinuation in migraine","volume":"31","author":"C Romero Del Rinc\u00f3n","year":"2024","journal-title":"Eur J Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(25)00109-6","article-title":"Calcitonin generelated peptide-targeted therapy in migraine: current role and future perspectives","volume":"405","author":"J Versijpt","year":"2025","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s10194-021-01281-z","article-title":"Comorbidities of primary headache disorders: a literature review with metaanalysis","volume":"22","author":"V Caponnetto","year":"2021","journal-title":"J Headache Pain"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-020-1084-y","article-title":"Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study","volume":"21","author":"DC Buse","year":"2020","journal-title":"J Headache Pain"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16106","article-title":"Depression and treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine","volume":"31","author":"S Vries Lentsch","year":"2024","journal-title":"Eur J Neurol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1111\/head.13970","article-title":"Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and\/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies","volume":"60","author":"TA Smitherman","year":"2020","journal-title":"Headache"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.clinthera.2005.02.013","article-title":"Topiramate monotherapy in epilepsy and migraine prevention","volume":"27","author":"SD Silberstein","year":"2005","journal-title":"Clin Ther"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"DW Dodick","year":"2010","journal-title":"Headache"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the doubleblind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"SK Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"ref30","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209584","article-title":"Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial","volume":"103","author":"PJ Goadsby","year":"2024","journal-title":"Neurology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231159366","article-title":"Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials","volume":"43","author":"F Haghdoost","year":"2023","journal-title":"Cephalalgia"},{"key":"ref32","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231156922","article-title":"Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis","volume":"43","author":"S Giri","year":"2023","journal-title":"Cephalalgia"},{"key":"ref33","first-page":"1","article-title":"Switching between anti-CGRP monoclonal antibodies in migraine prophylaxis","volume":"5","author":"M Vikelis","year":"2025","journal-title":"Expert Rev Neurother"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/head.14903","article-title":"Pharmacological differences and switching among anti-CGRP monoclonal antibodies: A narrative review","volume":"65","author":"M Romozzi","year":"2025","journal-title":"Headache: J Head Face Pain"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s10194-025-02068-2","article-title":"GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures","volume":"26","author":"P Barbanti","year":"2025","journal-title":"J Headache Pain"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11916-024-01344-1","article-title":"Neuromodulation for Headache Management in Pregnancy","volume":"29","author":"L Smirnoff","year":"2025","journal-title":"Curr Pain Headache Rep"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251327387","article-title":"OnabotulinumtoxinA treatment for chronic migraine in pregnancy: An updated report of real-world headache and pregnancy outcomes over 14 years in Hull","volume":"45","author":"HT Wong","year":"2025","journal-title":"Cephalalgia"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S1474-4422 (23)00206-5","article-title":"Migraine in older adults","volume":"22","author":"SS Hugger","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/ene.14268","article-title":"European Academy of Neurology guideline on the management of medication-overuse headache","volume":"27","author":"HC Diener","year":"2020","journal-title":"Eur J Neurol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s10194-024-01813-3","article-title":"Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache \u2013 a retrospective real-world analysis","volume":"25","author":"A Scheffler","year":"2024","journal-title":"J Headache Pain"},{"key":"ref41","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032600","article-title":"Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact","volume":"102","author":"CC Turkel","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/B978-0-12-823356-6.00008-1","article-title":"Chronic migraine and medication overuse","volume":"198","author":"HC Diener","year":"2023","journal-title":"Handb Clin Neurol"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2752-2800.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T23:30:35Z","timestamp":1771889435000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2752-2800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":41,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2026,2,23]]},"published-print":{"date-parts":[[2026,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2752-2800","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}